Your browser doesn't support javascript.
loading
Amitriptilina para el tratamiento de la neuropatía diabética periférica dolorosa / Amitriptyline for the treatment of painful peripheral diabetic neuropathy
Rojas Velasco, Giovanni.
  • Rojas Velasco, Giovanni; Hospital Vozandes Quito. Medicina Familiar. Quito. EC
VozAndes ; 23(1): 51-52, 2012.
Article in Spanish | LILACS | ID: biblio-1016455
RESUMEN
La prevalencia de neuropatía periférica dolorosa en pacientes diabéticos es de aproximadamente 16%. Esta condición clínica afecta de manera importante la calidad de vida de los pacientes. Además, se conoce que la adherencia de los pacientes es menor para fármacos que alivian el dolor, en relación a antidiabéticos orales. Los factores más relevantes para esto son el costo de los medicamentos, el potencial benefcio que se podría obtener con su administración y estados emocionales como la depresión, este último asociado también al no consumo de antidiabéticos orales [1, 2]. Las alternativas farmacológicas de primera línea contra el dolor de la neuropatía diabética periférica incluyen los antidepresivos tricíclicos (como amitriptilina), inhibidores selectivos de la recaptación de serotonina y noradrenalina (duloxetina) y los anticonvulsivantes gabapentina y pregabalina [1]. De estos fármacos, la amitriptilina ha sido una alternativa tradicional y los otros son opciones más modernas. En este contexto, se formuló en formato PICO (paciente ­ intervención ­ comparación ­ resultados) la siguiente pregunta ¿En pacientes con neuropatía diabética periférica dolorosa, el uso de amitriptilina en relación con gabapentina, pregabalina y duloxetina; controla adecuadamente el dolor?
ABSTRACT
The prevalence of painful peripheral neuropathy in diabetic patients is of approximately 16%. This clinical condition significantly affects the quality of life of patients. In addition, it is known that adhesion of patients is less for drugs that relieve pain, in relation to oral antidiabetics The most relevant factors for this are the cost of medications, the potential benefit that could be obtained with its administration and emotional states such as depression, the latter associated also to the non-consumption of oral antidiabetics. The first line pharmacological alternatives against the pain of neuropathy Peripheral diabetics include tricyclic antidepressants (such as amitriptyline), selective serotonin and norepinephrine reuptake inhibitors (duloxetine) and Gabapentin and pregabalin anticonvulsants. Of these drugs, amitriptyline It has been a traditional alternative and the others are more modern options. In this context, the following question was asked in PICO format (patient - intervention - comparison - results) In patients with painful peripheral diabetic neuropathy, the use of amitriptyline in relation to gabapentin, pregabalin and duloxetine; properly control pain?
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Diabetes Mellitus, Type 2 / Pain Management / Amitriptyline Type of study: Risk factors Limits: Humans Language: Spanish Journal: VozAndes Journal subject: Medicine Year: 2012 Type: Article Affiliation country: Ecuador Institution/Affiliation country: Hospital Vozandes Quito/EC

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Diabetes Mellitus, Type 2 / Pain Management / Amitriptyline Type of study: Risk factors Limits: Humans Language: Spanish Journal: VozAndes Journal subject: Medicine Year: 2012 Type: Article Affiliation country: Ecuador Institution/Affiliation country: Hospital Vozandes Quito/EC